Search the Newsreel

CRISPR Therapeutics reports $91.2 million second quarter net loss

CRISPR Therapeutics (CRSP) reported a net loss of $91.2 million for the second quarter of 2026, a significant improvement from the $208.5 million loss in the same period last year, while total revenue increased to $10.2 million. The company's gene-editing therapy, CASGEVY, generated $76 …

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss of $0.94 per Share

CRISPR Therapeutics AG (CRSP) reported a Q2 loss of $0.94 per share on revenue of $10.18 million, missing analyst revenue estimates but exceeding them on earnings per share. The company saw significant growth in revenue from its lead drug, CASGEVY, with a 151% year-over-year …

CRISPR Therapeutics (CRSP) Expected to Release Earnings on Monday

CRISPR Therapeutics (CRSP) is anticipated to release its Q2 2026 earnings on Monday, August 10th, with analysts forecasting a loss of $1.20 per share and revenue of $7.45 million. The company's shares are currently trading near their 52-week low, and it remains unprofitable, though …

CRISPR Therapeutics (CRSP) Rebounded In Its Latest Session, Is It Still Well Below Fair Value?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. CRISPR Therapeutics Stock Reaction To Recent Trading Session CRISPR Therapeutics (NasdaqGM:CRSP) recently finished a trading session with a positive price move that outpaced the S&P …

CRSP Stock Price and Chart — NASDAQ:CRSP

This page provides a comprehensive overview of CRISPR Therapeutics AG (CRSP) stock, including its current price, historical performance, key financial statistics, and company details. It also features a collection of recent news and trading ideas from analysts and community members regarding CRSP's stock movement, …

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Crispr Therapeutics AG (CRSP) and GlaxoSmithKline (GB:GSK)

This article discusses mixed analyst opinions on two healthcare stocks: Crispr Therapeutics AG (CRSP) and GlaxoSmithKline (GB:GSK). Crispr Therapeutics received a "Moderate Buy" consensus with an attractive price target upside, while GlaxoSmithKline holds a "Hold" consensus with a modest upside. The report highlights specific …

CRISPR Therapeutics AG (CRSP) Financial Health: Profitability & Balance Sheet Analysis

CRISPR Therapeutics AG (CRSP) has a weak financial status with a current financial score of 6.45, ranking 242 out of 384 in its industry. Despite a 68.55% year-over-year revenue increase to $1.46M and a 9.61% net profit increase, its operating efficiency is low. The …

Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy?

Key Points CRISPR Therapeutics recently won a key label expansion. The company has important data readouts on the horizon. The stock is somewhat risky given the possibility of clinical failures. 10 stocks we like better than CRISPR Therapeutics › CRISPR Therapeutics(NASDAQ: CRSP) has had …

CRISPR Therapeutics AG (CRSP) Exceeds Market Returns: Some Facts to Consider

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $48.44, demonstrating a +1.68% change from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 1.66%. Elsewhere, the Dow saw an upswing of 1.19%, while the …

Curis, Inc. (Nasdaq: CRIS) regains bid price compliance under one-year monitor

Curis, Inc. announced it has regained compliance with Nasdaq's bid price requirement (Listing Rule 5550(a)(2)) as of July 24, 2026, and is in full compliance with prior Nasdaq Hearings Panel conditions. However, the company will be subject to a one-year Discretionary Panel Monitor, during …

Curis doses first five patients in leukemia drug study

Curis Inc. announced that it has dosed the first five patients in its TakeAim CLL study for chronic lymphocytic leukemia, evaluating emavusertib combined with zanubrutinib. The company expects to release initial data from 5-10 patients in December 2026 and highlighted that patient enrollment is …

CRIS Looks 246.6% Overvalued on GF Value™

Curis Inc (NASDAQ: CRIS) is significantly overvalued by 246.6% based on GuruFocus's GF Value™ metric, trading at $5.03 against an intrinsic value of $1.45. This assessment comes despite the company's progress in its TakeAim CLL clinical trial, with preliminary data expected in December 2026. …

CRIS|Curis Inc|Price:4.975|Chg%:+0.145

This article provides a comprehensive stock analysis of Curis Inc (CRIS) by TradingKey. It highlights that Curis Inc's fundamentals are stable, with significant growth potential, and its valuation is considered fairly valued within the Biotechnology & Medical Research industry. The company shows high institutional …

Curis Pairs Emavusertib With Zanubrutinib in CLL Study

Curis (NASDAQ: CRIS) announced a significant enrollment milestone in its TakeAim CLL study, having dosed the first five patients. This study evaluates emavusertib, an IRAK4/FLT3 inhibitor, combined with the BTK inhibitor zanubrutinib, aiming for deeper responses in Chronic Lymphocytic Leukemia by achieving dual NF-kB …

How Crispr Therapeutics Ag (CRSP) Affects Rotational Strategy Timing

This article analyzes Crispr Therapeutics Ag (NASDAQ: CRSP) using AI models to provide trading strategies. It highlights weak sentiment across all horizons, suggesting a short bias, and details position, momentum breakout, and risk hedging strategies with specific entry, target, and stop-loss levels. The analysis …

Price to earnings forward of CRISPR Therapeutics AG Shs Thailand Depositary Receipts Repr 1 Sh – SET:CRSP03

This article focuses on the "Price to earnings forward" metric for CRISPR Therapeutics AG Shs Thailand Depositary Receipts, traded on the Stock Exchange of Thailand under the symbol CRSP03. It's a financial data point from TradingView, indicating a specific period, value, and change for …

Curis Inc (CRIS) Cash Flow

This article provides a detailed historical overview of Curis Inc.'s cash flow statements, including operating, investing, and financing activities, spanning from FY2012Q1 to FY2026Q1. It presents quarterly and annual financial figures, highlighting key metrics like operating cash flow, net income from continuing operations, capital …

3 Mid-Cap Growth Stocks With Monstrous Long-Term Upside

Investing in stocks with modest valuations can set investors up for some significant returns in the long run. While there is more risk involved in putting money into smaller, less-established businesses, the upside can also be considerable, potentially resulting in massive gains. Three mid-cap …

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

CRISPR Therapeutics AG (CRSP) has garnered investor attention, appearing on Zacks.com's list of most searched stocks. Despite a recent share decline, the article highlights the importance of earnings estimate revisions, revenue growth potential, and valuation in assessing the stock's future. CRISPR Therapeutics currently holds …

Curis Inc (CRIS) Institutional Confidence

Curis Inc (CRIS) has an institutional shareholding score of 3.00, placing it 192nd out of 386 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 24.60%, marking a significant quarter-over-quarter decrease of 37.31%. James Simons is the largest institutional shareholder, holding …

BlackRock (CRSP holder) discloses 7.99M-share, 8.3% stake in CRISPR Therapeutics

BlackRock, Inc. has filed an amended ownership report, disclosing a beneficial ownership of 7,987,262 shares, or an 8.3% stake, in CRISPR Therapeutics AG common stock. The filing, a SCHEDULE 13G/A, indicates that BlackRock holds sole voting power over 7,841,979 shares and sole dispositive power …

Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. On Wednesday, Curis Inc. announced updated positive clinical trial results for its investigational drug emavusertib, alongside expanded trial timeline guidance. The biotechnology firm detailed key advances across …

CRISPR Therapeutics AG (CRSP) Cash Flow

This article provides a detailed cash flow statement for CRISPR Therapeutics AG (CRSP), covering quarterly and annual data for operating, investing, and financing activities. It includes key financial metrics like operating cash flow, net income from continuing operations, capital expenditures, and free cash flow …

CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

CRISPR Therapeutics AG (CRSP) is anticipated to exceed earnings estimates for the quarter ending June 2026, with an expected year-over-year increase in earnings and a significant rise in revenues. The company's positive Earnings ESP of +1.94% combined with a Zacks Rank #3 suggests a …

CRIS|Curis Inc|Price:5.190|Chg%:+0.300

Curis Inc. (CRIS) is a biotechnology company focused on developing therapies for cancer. Its pipeline includes emavusertib, an IRAK4 inhibitor undergoing clinical trials for lymphoma and leukemia, and other programs like Fimepinostat and CA-170. The company's financials indicate a market capitalization of $9.34M, and …

Curis Inc (CRIS) Income Statement - Tradingkey.com

This article provides a detailed quarterly and annual income statement for Curis Inc (CRIS), presenting financial data such as total revenue, operating expenses, net income, and earnings per share spanning from Q1 2012 to Q1 2026. It also includes key financial metrics like operating …

Curis Market Sentiment

This article provides an overview of Curis (CRIS) market sentiment, detailing analyst consensus, short interest, options flow, and insider activity. It highlights a "Buy" consensus from 6 analysts with an average price target of $21, and notes a 0.7% declining short float. The piece …

Curis Inc (CRIS) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical dividend and stock split information for Curis Inc (CRIS). It notes that Curis Inc has not distributed any dividends over the past five years. The company has had several stock merger events, including one on June 25, 2026, and multiple …

CRISPR Therapeutics AG (CRSP) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for CRISPR Therapeutics AG (CRSP), noting its current earnings forecast score and industry ranking. It presents analyst ratings, target prices, and a peer comparison, along with expected EPS and revenue figures. The consensus among analysts is a "Buy" …

CRISM Therapeutics Corporation Revenue Breakdown – LSE:CRTX

Curis Inc (CRIS) Financial Health: Profitability & Balance Sheet Analysis

Curis Inc (CRIS) currently holds a weak financial status with a score of 5.36, ranking low within the Biotechnology & Medical Research industry. The company's operating efficiency is low, as evidenced by a significant 100.00% year-over-year decrease in quarterly revenue and a 127.95% decrease …

CRISPR Therapeutics (CRSP) Enters Phase 1 With CTX112 In Allogeneic CAR T

CRISPR Therapeutics (CRSP) has initiated Phase 1 clinical trials for its allogeneic CAR T candidate CTX112, targeting lymphoma and autoimmune diseases. This move expands the company's focus beyond gene editing, aiming to address critical issues of cost, manufacturing complexity, and access associated with current …

Curis, Inc. Revenue Breakdown – NASDAQ:CRIS

Curis, Inc. (NASDAQ: CRIS) reported a total revenue of $9.44 million USD last year. The entirety of this revenue came from its top-performing segment, Discovery and Development of Innovative Drug, with all revenue originating from the United States. This marks a decrease from the …

CRSP|CRISPR Therapeutics AG|Price:46.540|Chg%:-0.990

CRISPR Therapeutics AG (CRSP) is a Switzerland-based gene editing company with high growth potential, though its stock performance has been weak recently. The company's valuation is considered fair, and institutional ownership is very high. Analysts have rated it as a "Buy" with a significant …

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know

CRISPR Therapeutics AG (CRSP) saw its stock decline by 2.08% to $46.54, underperforming a market where the S&P 500 gained marginally. The company's shares have dropped 11.95% over the last month, lagging behind the Medical sector. Analysts forecast an EPS of -$1.1 and revenue …

CURIS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $43 FROM $17

H.C. Wainwright has significantly raised its target price for CURIS, INC. (CRIS.O) shares to $43 from the previous $17. This indicates a strong positive outlook from the analytical firm regarding the company's future performance or valuation. The article is a brief news alert from …